BWA
CYTK icon

Basecamp Wealth Advisors’s Cytokinetics CYTK Stock Holding History

Basecamp Wealth Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.9K Buy
222
+43
+24% +$3.09K ﹤0.01% 834
2026
Q1 		$11.8K Sell
179
-43
-19% -$2.73K ﹤0.01% 977
2025
Q4 		$14.1K Buy
+222
New +$13.8K ﹤0.01% 879

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Basecamp Wealth Advisors's CYTK Position: Q2 2026 in Review

Basecamp Wealth Advisors increased its Cytokinetics (CYTK) stake by 24% in Q2 2026, buying an estimated $3.09K and bringing the position to 222 shares worth $18.9K. The position accounts for ﹤0.01% of the portfolio, ranked #834.

Basecamp Wealth Advisors first reported a position in CYTK in Q4 2025 and has held it in 3 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Basecamp Wealth Advisors held 222 shares of Cytokinetics worth $18.9K as of Q2 2026.
  • Basecamp Wealth Advisors bought 43 Cytokinetics shares in Q2 2026, an estimated $3.09K.
  • Cytokinetics made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #834 holding.
  • Basecamp Wealth Advisors first reported a position in Cytokinetics in Q4 2025 and has held it in 3 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.